This is a non-core endpoint: only basic statistics are computed.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Medicine purchases: ATC
L03AX13
1 out of 7 registries used, show all original rules.
518
Check minimum number of events
Min. number of events
3
518
Include endpoints None
518
Remove individuals based on genotype QC
498
MSMED_GLATIRAMERACETATE
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
First used in FinnGen datafreeze
DF2
Not enough data for upset plot.
Or the full data table
Similar endpoints
↥List of similar endpoints to
Use of glatiramer acetate
based on the number of shared cases.
Broader endpoints:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Other degenerative diseases of the nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 498 | 417 | 81 |
| Unadjusted prevalence (%) | 0.12 | 0.18 | 0.04 |
| Mean age at first event (years) | 39.43 | 38.95 | 41.91 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: MSMED_GLATIRAMERACETATE – Use of glatiramer acetate
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Use of glatiramer acetate
↥Endpoint not on priority list, no data to show.